Marinomed Biotechnologie GmbH Granted European Patent for Anti-Viral Active Ingredient

Vienna, Austria, March 11, 2010 - Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that it has been granted the European Patent No.2101792, entitled ‘Use of Carrageenan for treating Rhinovirus infections’ by the European Patent Office.

Along with the antiviral polymer patent granted in April 2009, this patent covers a core component of Marinomed’s proprietory respiratory technology platform. Marinomed is using this platform to develop therapies that target more than 100 different respiratory virus strains. Respiratory viruses are responsible for some of the most common infectious diseases in humans such as the common cold and influenza. Specifically, this patent, which was granted in March 2010, protects the intellectual property for the active ingredient Carageenan.

Treatment options that are active against the majority of respiratory viruses are of particular importance for immunocompromised patients and patients suffering from COPD or asthma as common respiratory pathogens can exacerbate their conditions with severe consequences.

Based on this technology Marinomed has developed the first product – an antiviral nasal spray using Carageenan, which has marketing authorization in Europe. The benefits for patienst arising from products generated by this respiratory technology platform has been validated in clinical trials with adults and children. Marinomed intends to seek partners to market the nasal spray worldwide and to exploit the unique properties of the technology platform in additional products.

Dr Andreas Grassauer, CEO and co-founder of Marinomed, commented: “We are obviously delighted to have secured a second central patent protecting our technology platform and its use to develop safe and effective anti-viral treatments for respiratory illnesses. It puts Marinomed in a far stronger position when seeking international partners to work with in developing products.”

About Marinomed Biotechnologie GmbH

Marinomed Biotechnologie GmbH was founded in 2006 and develops therapies against respiratory diseases based on an innovative technology platform. The usability of this safe and effective technology has been proven by its first marketed product: an anti-viral nasal spray. The huge potential of the technology is reflected by Marinomed´s additional products concentrating on influenza, combination products for asthmatics and other high-risk patients. In addition, the Company develops a novel treatment against type I allergy and autoimmune diseases. Marinomed Biotechnologie GmbH is a spin-off from the Veterinary University Vienna and is located in Vienna, Austria. For further information please visit the website at www.marinomed.com